NasdaqGS:SCPH

Stock Analysis Report

Executive Summary

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.

Snowflake

Fundamentals

Excellent balance sheet and fair value.

Share Price & News

How has scPharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.5%

SCPH

-0.1%

US Pharmaceuticals

1.3%

US Market


1 Year Return

11.5%

SCPH

-6.6%

US Pharmaceuticals

5.9%

US Market

Return vs Industry: SCPH exceeded the US Pharmaceuticals industry which returned -6.6% over the past year.

Return vs Market: SCPH exceeded the US Market which returned 5.9% over the past year.


Shareholder returns

SCPHIndustryMarket
7 Day11.5%-0.1%1.3%
30 Day-18.6%-0.7%-1.9%
90 Day10.1%-2.7%-1.8%
1 Year11.5%11.5%-4.3%-6.6%8.3%5.9%
3 Yearn/a16.9%8.6%45.6%36.2%
5 Yearn/a27.3%13.9%66.1%47.9%

Price Volatility Vs. Market

How volatile is scPharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is scPharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: SCPH ($5.9) is trading below our estimate of fair value ($26.91)

Significantly Undervalued: SCPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SCPH is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: SCPH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SCPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCPH is good value based on its PB Ratio (1.7x) compared to the US Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is scPharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-1.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SCPH's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SCPH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if SCPH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has scPharmaceuticals performed over the past 5 years?

-17.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SCPH is unprofitable, and losses have increased over the past 5 years at a rate of -17.3% per year.

Accelerating Growth: Unable to compare SCPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: SCPH has a negative Return on Equity (-42.28%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SCPH is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SCPH is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is scPharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SCPH's short term assets ($81.8M) exceeds its short term liabilities ($13.5M)

Long Term Liabilities: SCPH's short term assets (81.8M) exceeds its long term liabilities (6.5M)


Debt to Equity History and Analysis

Debt Level: SCPH's debt to equity ratio (15.3%) is considered satisfactory

Reducing Debt: Insufficient data to determine if SCPH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: SCPH has a low level of unsold assets or inventory.

Debt Coverage by Assets: SCPH's debt is covered by short term assets (assets are 8.421520x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCPH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SCPH has sufficient cash runway for 1.748333 years if free cash flow continues to reduce at historical rates of -17% each year.


Next Steps

Dividend

What is scPharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SCPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SCPH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SCPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of scPharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

John Tucker (56yo)

2.8yrs

Tenure

US$1,491,307

Compensation

Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Chief Financial Officer sinc ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether John's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: SCPH's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

1.9yrs

Average Tenure

58yo

Average Age

Experienced Board: SCPH's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$1,052,62715 Apr 19
RA Capital Management, LLC
EntityCompany
Shares389,862
Max PriceUS$2.70

Ownership Breakdown


Management Team

  • Pieter Muntendam (61yo)

    Consultant

    • Tenure: 2.7yrs
    • Compensation: US$391.64k
  • Klaus Veitinger (57yo)

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: US$59.96k
  • John Tucker (56yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$1.49m
  • Mike Hassman

    Senior Vice President of Technical Operations

    • Tenure: 0yrs
  • Katherine Taudvin

    Director of Corporate Development & Investor Relations

    • Tenure: 0yrs
  • Rachael Nokes (44yo)

    Senior VP of Finance & Principal Accounting Officer

    • Tenure: 0.7yrs
  • John Mohr

    Senior Vice President of Clinical Development & Medical Affairs

    • Tenure: 0yrs

Board Members

  • Leonard Schaeffer (73yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$58.69k
  • Jack Khattar (58yo)

    Independent Chairman of the Board

    • Tenure: 1.9yrs
    • Compensation: US$92.46k
  • Mette Agger (55yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$64.66k
  • Klaus Veitinger (57yo)

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: US$59.96k
  • John Tucker (56yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$1.49m
  • Minnie Baylor-Henry (71yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$54.63k
  • Dorothy Coleman (56yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$63.48k
  • Frederick Hudson (73yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$68.78k
  • Mason Freeman (68yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$70.35k

Company Information

scPharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: scPharmaceuticals Inc.
  • Ticker: SCPH
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$109.627m
  • Shares outstanding: 18.58m
  • Website: https://www.scpharmaceuticals.com

Number of Employees


Location

  • scPharmaceuticals Inc.
  • 2400 District Avenue
  • Suite 310
  • Burlington
  • Massachusetts
  • 1803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCPHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
2SXDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017

Biography

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company’s lead product candidate is Furoscix that consists of prop ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:46
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.